2 results
Approved WMORecruiting
To assess the effect of donanemab versus placebo on clinical progression in participants with early symptomatic AD with demonstrated presence of low-medium tau pathology.
Approved WMOCompleted
Primary Objective: To assess the sensitivity and specificity of rhPSMA-7.3 (18F) PET in detecting N1 disease on a patient level compared to the histopathology of pelvic lymphatic tissue removed during RP and PLND. At least one positive pelvic LN on…